Matrix metalloproteinase-1, Matrix metalloproteinase-3, and Matrix metalloproteinase-9 (MMP-1, MMP-3, MMP-9)

Matrix metalloproteinase-1 (MMP-1), Matrix metalloproteinase-3 (MMP-3), and Matrix metalloproteinase-9 (MMP-9) are zinc-dependent endopeptidases that collectively regulate the degradation and turnover of the extracellular matrix (ECM) [UniProt P03956, P08254, P14780]. MMP-1, also known as interstitial collagenase, is specialized in breaking down fibrillar collagens (Types I, II, and III), while MMP-3 (stromelysin-1) possesses a broader substrate profile and plays a pivotal role in activating other pro-MMPs [PubMed: 28215559]. MMP-9, or gelatinase B, is primarily involved in degrading the basement membrane (Type IV collagen) and is a key mediator of leukocyte migration and tumor neoangiogenesis [PubMed: 12479116]. Pathologically, the over-expression of these enzymes is linked to tissue destruction in rheumatoid arthritis, plaque instability in atherosclerosis, and the invasion and metastasis of various cancers [StatPearls: Matrix Metalloproteinases]. Historically, therapeutic efforts focused on broad-spectrum inhibitors like Marimastat and Batimastat, which bind the catalytic zinc site to prevent substrate cleavage [PubMed: 10861316]. However, these clinical trials were largely unsuccessful due to the development of musculoskeletal syndrome (MSS), a dose-limiting toxicity characterized by joint pain and fibroplasia [PubMed: 12114520]. Modern drug development has shifted toward highly selective small molecules and monoclonal antibodies, such as Andecaliximab, which target specific MMP isoforms to improve the safety profile and therapeutic index [PubMed: 30104341].

Other names

Interstitial collagenaseFibroblast collagenaseStromelysin-1Transin-1Gelatinase B92 kDa type IV collagenaseCLGSTMY1GELB

Inhibition of enzymatic activity through competitive binding to the catalytic zinc ion or through monoclonal antibody-mediated neutralization of the protein [PubMed: 10861316, 30104341].